TFRC and neoplasm: In this study, we have developed NIR-activable, triple-receptor-targeted photoimmuno-nanoconjugates (TR-PINs) with three ligands, cetuximab (anti-EGFR mAb), holo-transferrin (natural ligand for TfR), and trastuzumab (anti-HER-2 mAb), conjugated to a single photosensitizing nanoconstruct to simultaneously target heterogeneous tumor cell subpopulations with differential expression levels of EGFR, TfR, and HER-2.